Selection of a BCR::ABL1 TKI for initial treatment of chronic phase CML

Selection of a TKI must consider the toxicity profile, comorbidities, availability, cost, and patient preference. Refer to related UpToDate topics for details of CML risk scoring, eligibility for TKI discontinuation to achieve TFR, outcomes, and adverse effects of individual BCR::ABL1 TKIs.